ArticleFrontiers in medicine2026
Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dry eye is a multifactorial ocular surface disorder in which tear hyperosmolarity acts as a major stressor that promotes inflammatory injury and apoptosis in corneal epithelial cells. Wogonoside (WGS), a flavonoid glycoside derived from Methods: Network pharmacology was used to identify putative targets shared by WGS and dry eye, followed by pathway enrichment analysis. Molecular docking, molecular dynamics simulation, and cellular thermal shift assay (CETSA) were further used to evaluate the interaction between WGS and AKT1. Experimental validation was performed in transformed human corneal epithelial cells (HCE-T cells) exposed to hyperosmotic medium (500 mOsm). Cell viability, proliferation, apoptosis, inflammatory mediator levels, and PI3K/AKT signaling-related changes were assessed. To interrogate pathway involvement, cells were additionally treated with the AKT activator SC79 (10 μM) or the AKT inhibitor MK-2206 (2.5 μM). Results: A total of 203 overlapping targets were identified between WGS-related and dry eye-related target sets. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment highlighted PI3K/AKT signaling as a potentially relevant pathway, and AKT1 was prioritized as a candidate target. Molecular docking and molecular dynamics simulation supported a stable interaction between WGS and AKT1, while CETSA provided additional evidence of AKT1 target engagement in cells. In hyperosmotic HCE-T cells, WGS improved cell viability and proliferative capacity, attenuated apoptosis, and reduced interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and matrix metalloproteinase-9 (MMP-9) levels. These effects were accompanied by restoration of PI3K/AKT signaling. Mechanistically, MK-2206 partially attenuated the protective effects of WGS, whereas SC79 produced a similar protective profile, supporting a PI3K/AKT-dependent component. Conclusion: Wogonoside alleviates hyperosmotic stress-induced inflammatory injury and apoptosis in HCE-T cells. Integrated evidence from network pharmacology, molecular docking, molecular dynamics simulation, CETSA, and
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.